Research programme: neuropeptide Y receptor agonists - 7TM Pharma
Latest Information Update: 07 Jul 2010
At a glance
- Originator 7TM Pharma
- Mechanism of Action Neuropeptide Y receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 09 May 2006 Preclinical trials in Metabolic disorders in Denmark (unspecified route)